Who are IC51 Japanese Encephalitis's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): JE Vaccine existing facility, JE vaccine new plant lot 1, JE vaccine new plant lot 2, Japanese Encephalitis purified inactivated vaccine, JE vaccine, JE-CV Vaccine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ic51-japanese-encephalitis.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

IC51 Japanese Encephalitis — Competitive Intelligence Brief

IC51 Japanese Encephalitis (IC51 Japanese Encephalitis) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inactivated viral vaccine. Area: Infectious Disease / Immunology.

phase 3 Inactivated viral vaccine Japanese encephalitis virus Infectious Disease / Immunology Biologic Live · refreshed every 30 min

Target snapshot

IC51 Japanese Encephalitis (IC51 Japanese Encephalitis) — Valneva Austria GmbH. IC51 is an inactivated Japanese encephalitis virus vaccine that stimulates the immune system to produce antibodies and cellular immunity against Japanese encephalitis virus.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
IC51 Japanese Encephalitis TARGET	IC51 Japanese Encephalitis	Valneva Austria GmbH	phase 3	Inactivated viral vaccine	Japanese encephalitis virus
JE Vaccine existing facility	JE Vaccine existing facility	International Centre for Diarrhoeal Disease Research, Bangladesh	marketed	Vaccine	Japanese encephalitis virus envelope proteins
JE vaccine new plant lot 1	JE vaccine new plant lot 1	International Centre for Diarrhoeal Disease Research, Bangladesh	marketed	vaccine	Japanese encephalitis virus envelope proteins
JE vaccine new plant lot 2	JE vaccine new plant lot 2	International Centre for Diarrhoeal Disease Research, Bangladesh	marketed	vaccine	Japanese encephalitis virus envelope proteins
Japanese Encephalitis purified inactivated vaccine	Japanese Encephalitis purified inactivated vaccine	Valneva Austria GmbH	phase 3	Inactivated viral vaccine	Japanese encephalitis virus antigens
JE vaccine	JE vaccine	Boryung Pharmaceutical Co., Ltd	phase 3	Vaccine	Japanese encephalitis virus envelope proteins
JE-CV Vaccine	JE-CV Vaccine	Sanofi Pasteur, a Sanofi Company	phase 3	Live attenuated chimeric vaccine	Japanese encephalitis virus and dengue virus (serotypes 1-4) structural antigens

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inactivated viral vaccine class)

Sinovac Biotech Co., Ltd · 9 drugs in this class
Sanofi Pasteur, a Sanofi Company · 9 drugs in this class
GlaxoSmithKline · 5 drugs in this class
Valneva Austria GmbH · 4 drugs in this class
Medical University of Vienna · 3 drugs in this class
Centers for Disease Control and Prevention · 3 drugs in this class
China National Biotec Group Company Limited · 2 drugs in this class
Statens Serum Institut · 2 drugs in this class
Institute of Medical Biology, Chinese Academy of Medical Sciences · 2 drugs in this class
Crucell Holland BV · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IC51 Japanese Encephalitis — Competitive Intelligence Brief. https://druglandscape.com/ci/ic51-japanese-encephalitis. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab